The clinical question remains as to whether stress is a trigger—or at least an exacerbating factor—in psoriasis and if so, how this should influence treatment approaches.
Researchers analyzed the relationship between migraines and psoriasis in the general US population, using data obtained from the 2003-2004 National Health and Nutrition Examination Survey (NHANES).
Machine learning identifies factors related to obesity, dyslipidemia, and inflammation as predictors of noncalcified coronary burden in patients with psoriasis, a study finds.
Patients with psoriasis who are naïve to biologic agents and patients who are within normal weight ranges may benefit the most from treatment with ustekinumab.
Physicians and patients report the impressive efficacy and safety profile of guselkumab for the treatment of moderate to severe psoriasis through 3 years of treatment.
A distinct association between psoriasis and metabolic and cardiovascular disorders is demonstrated in this study, which also found considerable sex differences in cardiovascular risk factors.
The biological treatment period represents a period of risk for HBVr and HCVr in patients with psoriasis receiving therapy, although prophylaxis with an anti-HBV agent significantly reduces the risk for HBVr.
The combination of apremilast and a biologic is a safe, useful treatment choice for managing patients with psoriasis who are experiencing biologic fatigue.
